Abstracts tagged "Biologics and treatment"

Abstract Number: 1540 • 2019 ACR/ARP Annual Meeting
Biologic Use and Reasons for Switching Biologic Therapy in Patients with Non-radiographic Axial Spondyloarthritis in the United States:Findings from a US Survey
Atul Deodhar ¹, Theresa Hunter², Elizabeth Holdsworth ³, Nicola Booth ⁴ and David Sandoval ⁵, ¹Oregon Health & Science University, Portland, OR, ²Eli Lilly and Company, Indianapolis, ³Adelphi Real World, Manchester, England, United Kingdom, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Eli Lilly and Company, Indianapolis, IN
Background/Purpose: The FDA approved the first biologic for the treatment of nr-axSpA in the US in March 2019. The objective of our study was to…
Abstract Number: 2857 • 2019 ACR/ARP Annual Meeting
Decision Tree Analysis to Identify Inflammatory Arthritis Patient Subgroups with Different Levels of Treatment Persistence with First-Line Subcutaneous TNF-alpha Inhibitors
Emma Hernlund ¹, Johan Klint ¹, Axel Svedbom ¹, Johan Dalén ¹, Christopher Black ² and Amy Puenpatom², ¹ICON plc, Stockholm, Sweden, Stockholm, Sweden, ²Merck & Co., Inc., Kenilworth, NJ, United States, Kenilworth, NJ
Background/Purpose: The advent of biologic medications, such as subcutaneous TNF-alpha inhibitors (SC-TNFi), has transformed the management of inflammatory arthritis (IA) during the last decades. However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].